<H1> Transplant Diagnostics Market on the rise due to early detection tech with 6â€“8% CAGR by 2029 </H1>
<img class="alignnone size-full wp-image-1866" src="http://dailyinvestorhub.com/wp-content/uploads/2025/06/Transplant-Diagnostics-Market-1.png" alt="" width="849" height="479" />

<strong><em>The </em></strong><a href="https://meditechinsights.com/transplant-diagnostics-market/"><strong><em>global transplant diagnostics market</em></strong></a><strong><em> is projected to grow at a CAGR of 6-8% over the next 5 years.</em></strong>Â The increasing prevalence of organ failure and growing awareness about organ transplantation are driving the demand for advanced transplant diagnostics. Technological advancements in molecular and genetic testing, alongside improving healthcare infrastructure in emerging regions, further fuel this marketâ€™s growth. Additionally, increased government funding for research on organ transplants and support for diagnostic innovations are also contributing to the expansion of the transplant diagnostics sector.

Transplant diagnostics involves an array of technologies, such as molecular assays, PCR, sequencing, and next-generation sequencing (NGS). These diagnostic tools are crucial for ensuring compatibility between donors and recipients, monitoring post-transplant rejection risks, and improving overall patient outcomes. Technologies like HLA typing and donor-specific antibody (DSA) testing play a pivotal role in reducing transplant rejection rates. Furthermore, real-time PCR and NGS technologies are enhancing transplant outcomes by providing rapid and accurate genetic matching and monitoring of transplant health.

<strong>ðŸ”— Want deeper insights? Download the sample report:
</strong><a href="https://meditechinsights.com/transplant-diagnostics-market/request-sample/">https://meditechinsights.com/transplant-diagnostics-market/request-sample/</a>

<strong>Growing number of organ transplant procedures is driving the market growth</strong>

The growing number of organ transplant procedures is a key driver in the expansion of the transplant diagnostics market. In 2023, the United States saw over 46,000 transplants, marking an 8.7% increase from the previous year. This growth is accompanied by a substantial rise in deceased donors, reaching more than 16,000, up by 9.6% compared to 2022. With more individuals in need of life-saving transplants, including kidneys, livers, hearts, and lungs, the demand for donor organs has intensified. The steady rise in organ donations and procedures not only highlights the increased willingness to donate but also underscores the pressing need for more advanced infrastructure to support this volume, which is reshaping the future of transplant care globally.

<strong>Growth Potential and Challenges for Transplant Diagnostics Market in Asia</strong>

There is high growth potential in the Asian transplant diagnostics market, though it faces some challenges. For instance, China has made significant strides in organ donation, with over 120100 major organs donated from 2015 to 2022. Additionally, more than 6.5 million people have registered as potential donors. This growing donor pool highlights the expanding market for transplant diagnostics, which supports organ compatibility testing and improves transplant success rates. However, there are challenges; organ donations per million people (PMP) remain below 4% in China, far behind developed countries at &gt;45%. Additionally, a limited number of hospitals and high transplant costs constrain access, underscoring a need for further infrastructure and policy support.

<strong>Gain a competitive edge-request a sample report now!</strong><strong>
</strong><a href="https://meditechinsights.com/transplant-diagnostics-market/request-sample/">https://meditechinsights.com/transplant-diagnostics-market/request-sample/</a>

<strong>Competitive Landscape Analysis</strong>

Key players in the global transplant diagnostics market includeÂ <strong>Thermo Fisher Scientific, Bio-Rad Laboratories,Â Illumina, Werfen (incl. Immucor, Omixon),Â Eurobio ScientificÂ (incl. GenDx), and Roche</strong>; among others. Strategic acquisitions have remained central to the competitive strategies of these companies, aimed at strengthening their market positions and expanding their product offerings.

<strong>About Medi-Tech Insights</strong>

Medi-Tech Insights is a healthcare-focused business research &amp; insights firm. Our clients include Fortune 500 companies, blue-chip investors &amp; hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices &amp; Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis &amp; go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

<strong>Contact:</strong>

Ruta Halde
Associate, Medi-Tech Insights
<u>Â +32 498 86 80 79
</u><a href="mailto:info@meditechinsights.com">info@meditechinsights.com</a><u>Â </u>
